News of the Day

Australian company QBiotics has announced the appointment of two experienced and senior medical executives to its leadership team. 

As it prepares to progress its merger with Sigma, Chemist Warehouse has updated investors, revealing a first-half result that saw like-for-like sales grow by 10 per cent.

The approach causes actual harm because it pre-legitimises the review and its outcomes. It gives the industry nowhere to go if things go wrong. It is now tied to the long-term consequences of a process that it knows is seriously flawed.

Medicines Australia has used its 2025-26 Pre-Budget Submission to argue for implementing all 50 recommendations included in the Health Technology Assessment Review final report.

Pharmaceutical manufacturer IDT Australia (ASX:IDT) has updated investors, reporting a significant rise in revenue for the final three months of the calendar year 2024.

The charter grants patients the right to access a treatment that meets their needs. However, they are denied any rights in determining funding for treatments that can address that need.

“I realised we had something special when our lead scientist on this programme came into my office and showed me some data related to the screening they'd been doing," said Dr Andrew Nash, CSL’s chief scientific officer.

“This year’s award winners demonstrate a wide-ranging commitment not only to our profession but most importantly, to their patients and community,” said Pharmacy Guild national president Professor Trent Twomey.

The TGA has approved Apellis Pharmaceuticals' SYFOVRE (pegcetacoplan) for the every-other-month treatment of adult patients with a form of age-related macular degeneration.

We return in 2025 with a discussion about our recently published special series on achieving change, arguing for it in a system that treats patients as servile to the government's focus on securing the best deal for itself, moral hazards, and bad excuses.

The release of Cabinet records from 2004 has revealed significant information on the PBS with policy discussions and decisions taken on the program that reverberate in 2025.

The HTA Review Implementation Advisory Group will hold its first official meeting in early February, and its members have been asked to sign confidentiality deeds.